Company intelligence / Profile preview

Novosanis

Ownership: Private
Employees: ~12
Development stage: Commercial

Overview

Novosanis develops innovative medical devices to improve the accuracy of diagnostic tests and drug delivery, focusing on self-sampling solutions. Its Colli-Pee™ device is CE-marked, FDA-listed, and commercially available for standardized first void urine collection to enhance detection of infectious diseases and early-stage cancers. The VAX-ID™ intradermal injection platform is in late development.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Device (for both injection and sample collection)
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on Novosanis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novosanis.

Explore the full profile